Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Respiratory physiology Stories

2013-11-08 08:27:43

WARRINGTON, Pa., Nov. 8, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that it has initiated the U.S. commercial launch of SURFAXIN(® )(lucinactant) Intratracheal Suspension for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS. SURFAXIN is the first FDA-approved synthetic, peptide-containing...

2013-10-24 16:27:17

Eleven presentations on investigational compounds and an approved product will be presented at the CHEST 2013 meeting RIDGEFIELD, Conn., Oct. 24, 2013 /PRNewswire/ -- Boehringer Ingelheim today announced the upcoming presentation of data from 11 abstracts, including 6 oral presentations, across the company's respiratory portfolio at the 2013 American College of Chest Physicians (ACCP) annual meeting, CHEST 2013, taking place October 26 - 31 in Chicago. These data exemplify...

2013-10-22 08:31:25

ANAHEIM, Calif., Oct. 22, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that it will commence a Phase 2 study to explore the efficacy and safety of H.P. Acthar® Gel (repository corticotropin injection) for Acute Respiratory Distress Syndrome (ARDS). The Company's Investigational New Drug (IND) application for the study has been reviewed by the U.S. Food and Drug Administration (FDA) and is now active. ARDS is an acute life-threatening lung condition...

2013-10-17 08:29:19

Important Neonatal Clinical Development Program Expected to Begin 4Q'13 WARRINGTON, Pa., Oct. 17, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate its AEROSURF(®) phase 2 clinical program. The FDA has confirmed receipt of...

2013-10-09 12:58:21

A simple video camera paired with complex algorithms appears to provide an accurate means to remotely monitor heart and respiration rates day or night, researchers report. The inexpensive method for monitoring the vital signs without touching a patient could have major implications for telemedicine, including enabling rapid detection of a heart attack or stroke occurring at home and helping avoid sudden infant death syndrome, according to a study published in the journal PLOS ONE. It...

2013-10-08 08:28:53

WARRINGTON, Pa., Oct. 8, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent entitled "Capillary System With Fluidic Element." The Company holds a license to this patent (U.S. Patent Application. No. 12/285,312), which will provide additional...

2013-10-04 08:23:33

Commercial Introduction of SURFAXIN Planned for the Fourth Quarter of 2013 WARRINGTON, Pa., Oct. 4, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN(® )(lucinactant) Intratracheal Suspension which was approved for the prevention of...

2013-09-26 16:27:31

SANGUINATE(TM) INCORPORATES MULTIPLE MECHANISMS OF ACTION TO TREAT THE COMORBIDITIES OF THE DISEASE SOUTH PLAINFIELD, N.J., Sept. 26, 2013 /PRNewswire/ -- Prolong Pharmaceuticals LLC, a biopharmaceutical company dedicated to developing products for the treatment of anemia resulting from oxygen deficiency and hemolysis, presented a novel approach to treating the comorbidities of sickle cell disease (SCD) at the 41(st) Sickle Cell Disease Association of America convention "Moving Forward:...

2013-09-26 08:26:53

MOUNTAIN VIEW, Calif., Sept. 26, 2013 /PRNewswire/ -- PneumRx, Inc., a leader in interventional pulmonology, announced that over 1500 procedures have been performed using the RePneu Lung Volume Reduction Coil (LVRC) System for patients with severe emphysema. (Logo: http://photos.prnewswire.com/prnh/20120514/SF06703LOGO) The RePneu LVRC is a minimally invasive device intended to improve lung function, exercise capacity and quality of life in emphysema patients by bronchoscopically...

2013-09-25 23:35:56

Avail is conducting a 24-week study to evaluate the effect of a once-daily experimental inhalation therapy on arterial stiffness compared to a placebo and another drug in subjects with Chronic Obstructive Pulmonary Disease (COPD). DeLand, Florida (PRWEB) September 25, 2013 *To see if you qualify for this COPD Clinical Trial in Florida, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost to participate, no...